Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of rilvegostomig plus bevacizumab with or without tremelimumab as first-line treatment for hepatocellular carcinoma
CTR20251317Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of rilvegostomig, bevacizumab, tremelimumab, atezolizumab in hepatocellular carcinoma (HCC), sponsored by AstraZeneca. Started Jun 2025; status: active.
02
Drugs
rilvegostomigbevacizumabtremelimumabatezolizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20251317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251317.